Join to view full profile
6400 Fannin StSuite 2900Houston, TX 77030
Phone+1 832-325-7702
Fax+1 713-512-7132
Join Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 4 invites waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Hazem El-Osta, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Louisiana, and Louisiana. He is an Assistant Professor at LA State Univ Sch of Med.
Education & Training
Louisiana State University School of MedicineFellowship, Hematology and Medical Oncology, 2010 - 2013
University of Kansas (Wichita)Residency, Internal Medicine, 2006 - 2009
St Joseph's University Medical SchoolClass of 2004
Certifications & Licensure
TX State Medical License 2016 - 2027
LA State Medical License 2010 - 2026- LA State Medical License 2010 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 1 citationsErratum to "Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (...Maria Carmela Piccirillo, Quincy Chu, Penelope Bradbury, Wei Tu, Courtney H Coschi
Journal of Thoracic Oncology. 2024-11-01 - 18 citationsBrief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171).Maria Carmela Piccirillo, Quincy Chu, Penelope Bradbury, Wei Tu, Courtney H Coschi
Journal of Thoracic Oncology. 2023-06-01 - 21 citationsReal-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data.Vamsidhar Velcheti, Xiaohan Hu, Yeran Li, Hazem El-Osta, M Catherine Pietanza
Cancers. 2022-02-18
